Alnylam Pharmaceuticals Inc to Discuss FDA Approval of OXLUMO (Lumasiran) Conference Call Transcript
Ladies and gentlemen, thank you for standing by. Welcome to Alnylam Pharmaceuticals Conference call to discuss our approval of OXLUMO. (Operator Instructions) Please be advised that this call is being taped at the company's request.
I'd now like to turn the call over to the company. Please go ahead.
Good morning. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today are John Maraganore, our Chief Executive Officer; Akshay Vaishnaw, our President of R&D; and Andy Orth, our Senior Vice President, Head of U.S. Business. Also joining us and available for Q&A are Yvonne Greenstreet, our President and Chief Operating Officer; and Pritesh Gandhi, General Manager of the Lumasiran program.
For those of you participating via conference call, the slides that is made available via webcast can also be accessed by going to the Investor page of our website,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |